Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05863052

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
72 (estimated)
Sponsor
University of Oklahoma · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

Detailed description

Immune checkpoint inhibitors have been shown to increase survival in metastatic solid tumor patients when compared to the previously standard of care chemotherapy. Epidemiologic studies of American Indian cancer patients demonstrated having significantly worse survival when compared with Caucasians when controlled for age, sex, alcohol abuse, smoking, insurance, and disease stage. There are no current studies specifically examining the American Indian population receiving treatment with immune checkpoint inhibitors. The aim is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

Conditions

Interventions

TypeNameDescription
BIOLOGICALImmunotherapyimmunotherapy

Timeline

Start date
2022-01-31
Primary completion
2026-12-01
Completion
2027-12-01
First posted
2023-05-17
Last updated
2026-02-10

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05863052. Inclusion in this directory is not an endorsement.